Genicular Artery Embolization (GAE) with First-in-Human Resorbable Microspheres

GAE for Knee Osteoarthritis: The Resorbable Solution This episode explores the first-in-human trial of Sakura, a novel resorbable alginate microsphere designed specifically to solve the safety trade-offs of Genicular Artery Embolization (GAE) for knee osteoarthritis. The Problem with Current Agents: We discuss why Interventional Radiologists have been stuck between using permanent particles (risk of skin ulcers/long-term pain) and off-label temporary agents (unpredictable resorption, antibiotic resistance). The Bio-Innovation: This new device features an "internal timer"—an enzyme trapped inside the bead that activates upon hydration, ensuring predictable degradation within just 1 to 2 hours. Safety Game-Changer: The trial showed zero serious adverse events. Crucially, non-target skin redness resolved in just 2 hours, compared to weeks with traditional agents, drastically improving the safety profile. Efficacy vs. Speed: Despite the rapid resorption, patients achieved a 77% reduction in pain at 3 months, and 93% stopped taking pain medication entirely, suggesting that a brief ischemic "reset" is all that is needed to stop the pain cycle. Tune in to see how this "self-destructing" particle could redefine the standard of care for chronic knee pain. Based on comments from experts, content on Wysdom, and the article cited below. Little MW, Agarwal S, Khikmatovich IM, McCabe J, Pandey M, Lewis AL, Farrissey L, Iskhakov SA. First-in-Human Evaluation of a New Resorbable Microspherical Embolic Agent for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteroarthritis. J Vasc Interv Radiol. 2025 Nov;36(11):1658-1666. doi: 10.1016/j.jvir.2025.07.010. Epub 2025 Jul 18. PMID: 40685121.